Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
Disc Medicine said its Phase 3 APOLLO trial of bitopertin met all primary and secondary endpoints. The company plans to resubmit its NDA by the end of 2026, with an FDA decision expected by mid-2027.
The company says bitopertin met all primary and secondary endpoints in the pivotal APOLLO trial in adults and adolescents with erythropoietic protoporphyria.